Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery

Wu, Yahua; Li, Jiancheng

doi:10.2147/cmar.s295646

Cited by 11 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 The other variables (SII, SIRI and PNI) were calculated by the following formula: PNI = ALB (g/L) +5 × LY (10 9 /L), SII = PLT × NEUT/LY and SIRI = MONO × NEUT/LY. 17 , 18 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores

Feng¹,

Wang²,

Yang³

et al. 2022

JIR

View full text Add to dashboard Cite

Purpose Neoadjuvant immunotherapy and chemotherapy (nICT) is an emerging hotspot that has been shown to be safe and feasible for locally advanced esophageal squamous cell carcinoma (LA-ESCC). This real-world study aimed to develop and validate a novel predictive model [integrative inflammatory and nutritional score (IINS)] in LA-ESCC patients receiving nICT to predict the pathologic complete response (pCR). Patients and Methods Patients with LA-ESCC who received nICT followed by surgery from Jun 2019 to Dec 2021 were enrolled and randomly divided into two sets (7:3). Using least absolute shrinkage and selection operator (LASSO) logistic regression analysis, the IINS was constructed in LA-ESCC patients received nICT to predict pCR. A nomogram based on IINS for pCR prediction was generated in the training cohort and verified in the validation cohort. Results Of the 285 enrolled LA-ESCC patients received nICT followed by radical resection, 84 (29.5%) patients achieved pCR. A predictive index of IINS based on 8 inflammatory and nutritional indicators was constructed using the LASSO model. According to the cutoff finder, patients were then stratified into two groups (high and low). The pCR rates were significantly higher in high-IINS group than in low-IINS group in both the training cohort (44.7% vs 17.4%, P < 0.001) and validation cohort (50.0% vs 13.3%, P < 0.001). The IINS [odds ratio (OR) = 0.237, 95% confidence interval (CI) = 0.117–0.480, P < 0.001] was an independent significant predictor for pCR in multivariate logistic analyses. The IINS-based nomogram showed an excellent discrimination for pCR prediction (C-indexes = 0.759 and 0.812 for training and validation cohorts, respectively). Conclusion Pretreatment IINS is an independent predictor for pCR in LA-ESCC patients who are treated with nICT. To our knowledge, the IINS-based nomogram is the first model for pCR prediction and may serve as a simple and potential risk stratification model in LA-ESCC who are treated with nICT.

show abstract

“… 28 The other variables (SII, SIRI and PNI) were calculated by the following formula: PNI = ALB (g/L) +5 × LY (10 9 /L), SII = PLT × NEUT/LY and SIRI = MONO × NEUT/LY. 17 , 18 …”

Section: Methodsmentioning

confidence: 99%

“…Therefore, more and more integrative hematological indicators, including systemic inflammation response index (SIRI), systemic immune-inflammation index (SII) and prognostic nutritional index (PNI), were also applied for pCR prediction after nCRT in several cancers. 17 , 18 …”

Section: Introductionmentioning

confidence: 99%

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores

Feng¹,

Wang²,

Yang³

et al. 2022

JIR

View full text Add to dashboard Cite

show abstract

“…Although some tumor cells were killed after radiotherapy, there was little change in the maximum tube wall thickness ( 22 – 24 ). Wu's team found that in patients with esophageal cancer undergoing radiotherapy and chemotherapy, the percentage of maximum wall thickness reduction was independently associated with pathological complete response ( p = 0.027), and could predict the recurrence of the disease ( 25 ). Wongwaiyut's team found that the survival of patients with esophageal cancer with a maximum wall thickness of <10 mm and ≥10 mm was different, and the larger the maximum wall thickness, the worse the prognosis of patients ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Application Value of Gastroenterography Combined With CT in the Evaluation of Short-Term Efficacy and Prognosis in Patients With Esophageal Cancer Radiotherapy

Xue

Linning

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

PurposeTo observe the application value of gastroenterography combined with CT in the evaluation of short-term efficacy and prognosis in patients with esophageal cancer radiotherapy.MethodsFrom January 2013 to December 2020, the clinical data of 207 patients with esophageal cancer treated by radiotherapy in our hospital were collected retrospectively. All patients received gastroenterography and CT examination before and after radiotherapy, and the patients were followed-up for 1 year, and the evaluation value of their short-term efficacy and prognosis was observed.ResultsAfter radiotherapy, the length diameter, short diameter, and volume of the lymph node were lower than those before radiotherapy (p < 0.05), but the maximum tube wall thickness had no significant difference (p > 0.05). The length diameter, short diameter, and volume of the lymph node, and the maximum tube wall thickness in the good efficacy group and the good prognosis group were lower, and the objective response rate in the good prognosis group was higher (p < 0.05). The area under the curve (AUC) of the length diameter, short diameter, and volume of the lymph node to evaluate the short-term efficacy of patients with esophageal cancer was 0.738, 0.705, and 0.748, respectively, and the AUC to evaluate the prognosis of patients with esophageal cancer was 0.751, 0.776, and 0.791, respectively.ConclusionGastroenterography combined with CT has a good application value in the evaluation of short-term efficacy and prognosis in patients with esophageal cancer radiotherapy.

show abstract

“…Accurate prediction of the pCR before surgery is crucial for the decision of whether to continue observation or radical surgery in the observation period after nCRT. A single-center retrospective study ( 63 ) with 146 ESCC patients treated with nCRT concluded that a ≤40% reduction in the maximal esophageal wall thickness following nCRT was strongly related to low pCR rate, short survival time, and high risk of recurrence. However, the prediction of the efficacy of nCRT-based CT alone is insufficient.…”

Section: The Strategies To Accurately Predict the Efficacy Of Neoadju...mentioning

confidence: 99%

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

Han

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Over 50% of individuals with esophageal cancer (EC) present with advanced stages of the disease; therefore, their outcome following surgery alone is poor, with only 25%–36% being alive 5 years post-surgery. Based on the evidence that the CROSS and NEOCRTEC5010 trials provided, neoadjuvant chemoradiotherapy (nCRT) is now the standard therapy for patients with locally advanced EC. However, there are still many concerning clinical questions that remain controversial such as radiation dose, appropriate patient selection, the design of the radiation field, the time interval between chemoradiotherapy (CRT) and surgery, and esophageal retention. With immune checkpoint inhibitors (ICIs) rapidly becoming a mainstay of cancer therapy, along with radiation, chemotherapy, and surgery, the combination mode of immunotherapy is also becoming a hot topic of discussion. Here, we try to provide constructive suggestions to answer the perplexing problems and clinical concerns for the progress of nCRT for EC in the future.

show abstract

Change in Maximal Esophageal Wall Thickness Provides Prediction of Survival and Recurrence in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy and Surgery

Cited by 11 publications

References 28 publications

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores

Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores

Application Value of Gastroenterography Combined With CT in the Evaluation of Short-Term Efficacy and Prognosis in Patients With Esophageal Cancer Radiotherapy

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review

Contact Info

Product

Resources

About